---
title: "Longtech: Pengcheng Denggao and Pengcheng Zhanchi plan to collectively reduce their holdings by no more than 3% of shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247656194.md"
description: "According to the Zhitong Finance APP, Longtech announced that the employee stock ownership platforms Pengcheng Denggao and Pengcheng Zhanchi plan to reduce their holdings in the company, with a total number not exceeding 4.33932 million shares, which is no more than 3.00% of the company's current total share capital"
datetime: "2025-07-08T13:06:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247656194.md)
  - [en](https://longbridge.com/en/news/247656194.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247656194.md)
generator: "portal-rs"
---

# Longtech: Pengcheng Denggao and Pengcheng Zhanchi plan to collectively reduce their holdings by no more than 3% of shares

According to the Zhitong Finance APP, Longtech (300916.SZ) announced that the employee shareholding platforms Pengcheng Denggao and Pengcheng Zhanchi plan to reduce their holdings in the company, with a total number not exceeding 4.33932 million shares, which is no more than 3.00% of the company's current total share capital

### Related Stocks

- [300916.CN](https://longbridge.com/en/quote/300916.CN.md)

## Related News & Research

- [04:04 ETLa célébration du 11e anniversaire d'Anycubic approche : 11 ans, 11 millions d'idées](https://longbridge.com/en/news/297285709.md)
- [Canada minister says he welcomes US clarification on French language requirements](https://longbridge.com/en/news/297196718.md)
- [Heidelberg Pharma, Huadong Medicine expand ADC collaboration to develop new drug candidates](https://longbridge.com/en/news/297291658.md)
- [Heidelberg Pharma says China NMPA clears HDP-101 combo trial in multiple myeloma](https://longbridge.com/en/news/297070749.md)
- [13:00 ETAPS Expands UPI High Output Alternator Line for Growing Power Needs in Luxury Motorcoaches](https://longbridge.com/en/news/297215641.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**